Blog

Latest news about encapsia

Sponsors agree the coronavirus pandemic exposed shortcomings of existing processes in clinical trials

Written by David Connelly, CEO
03 Aug 2020

Modern technologies support agile processes for clinical trials

95% of attendees to our webinar this week agreed with the central message that processes and supporting technologies commonly used in clinical trials are outdated, and furthermore they contributed to the huge disruption of clinical trials caused by the COVID-19 pandemic.

Systems and methods for data collection, monitoring, review and analysis have evolved in a piecemeal fashion, and whether well suited or not, are normally “bolted together”. Not surprisingly they provide inflexible, high cost solutions, riddled with limitations and workarounds that struggle to meet the needs of sponsors and modern clinical trials. Most clinical trial data isn’t even captured or managed in Electronic Data Capture systems. COVID-19 has shone a spotlight on them and ruthlessly revealed their flaws.

Data systems are not peripheral. Put simply, the core output of a clinical trial is data, used to derive critical information for decisions on efficacy and safety. Data quality and integrity are critical. And many ongoing clinical trials will now face data challenges because of the disruption caused by COVID-19.

The industry needs a new approach that puts clinical data at the core and applies the capabilities of modern, flexible technologies to combine different types of trial data in a changing world for rapid and thorough analysis. Not only will this approach streamline current processes, but technologies like encapsia can also support new processes, as encapsia is a very agile system able to respond to a rapidly changing environment. For example it can seamlessly mix data capture via web EDC, direct data capture eSource and a mobile home visit app that even works without a steady internet connection.

In another example of system flexibility, encapsia was rapidly enabled in response to COVID-19 so that sites could easily provide source data for remote review, using a new app for smartphones with strict privacy controls.

Click here to see a recording of our webinar, “COVID-19: The catalyst for long overdue change in clinical trial technologies and processes”


For a no obligation discussion with one of our clinical trial experts about processes that put clinical data at the core of clinical trials please contact:

Jay Conze in US
jconze@cmedresearch.com (919) 595 - 1115
or Maria Iliescu in Europe
miliescu@cmedresearch.com +40 (0)356 433 977


Last 3 posts

Modern technologies support agile processes for clinical trials 95% of attendees to our webinar this week agreed with the central message that processes and supporting technologies commonly used in clinical trials are outdated, and furthermore they contributed to the huge disruption of clinical trials caused by the COVID-19 pandemic. Systems and methods for data collection, monitoring, review and analysis have evolved in a piecemeal fashion, and whether well suited or not, are normally “bolted together”.
This was one of several deliberately thought-provoking questions raised in our webinar last month, “COVID-19: The catalyst for long overdue change in clinical trial technologies and processes”. In the first session, Gurpal Ahluwalia (Partner at BDO Life Sciences) assessed the disruptive impact of COVID-19 on clinical trials and the reasons why the industry has found itself in such difficulty. Cmed CEO, David Connelly, then shared some further perspective on the shortcomings of existing technologies and processes and suggested these contributed to the degree of disruption caused by the pandemic.
Question: Your webinar presentation earlier this week was quite provocative. Could you tell us a bit more about your background? TCC: I started writing software and building computers from scratch from a very early age. My father and I ran an educational software company when I was a teenager, and then I went on to read Engineering and Computer Science at Oxford, capping this with a DPhil in AI before co-founding Cmed Technology - a lifetime writing, designing and creating enterprise platforms with a specialism and passion for the clinical trial space.